Biopharma · global
Oral antifungal new drug olorofim meets Phase 3 endpoint, opening a regulatory window for invasive aspergillosis
In invasive aspergillosis, where treatment options are limited and nephrotoxicity often affects treatment decisions, F2G and Shionogi’s OASIS trial brings an oral drug with a new mechanism one step closer to a marketing application; however, the publicly available data are still topline results, and the full efficacy and safety profile remains to be disclosed at a medical meeting.
Invasive aspergillosis often occurs in patients whose immune systems are at their most vulnerable, such as people with blood cancers, transplant recipients, or those receiving long-term immunosuppressive therapy; once standard azole antifungals fail, cannot be tolerated, or are unsuitable because of interactions, the paths available to physicians quickly narrow. The global Phase 3 OASIS trial announced by F2G and Shionogi on June 18 was aimed precisely at this group of clinically difficult-to-treat patients, evaluating whether oral olorofim could become another option.
According to the topline results released by the two companies, OASIS met its primary non-inferiority endpoint. All-cause mortality at Day 42 was 23.8% in the olorofim group and 24.3% in the control group, which received AmBisome followed by standard of care; the treatment difference was -0.5%, with a 95% confidence interval from -13.1% to 10.8%. This means that, under the non-inferiority framework set for the study, olorofim’s early mortality outcome was not inferior to a treatment strategy starting with liposomal amphotericin B.
The trial enrolled a total of 225 adults, randomized 2:1 to olorofim or AmBisome followed by standard of care. All participants had invasive aspergillosis, and their infections had responded poorly to azole therapy, or they were unsuitable for azole drugs because of other factors. This design makes the results more closely reflect one of the most challenging phases of disease in clinical practice: not typical treatment-naive patients, but a population whose treatment options have already been compressed by toxicity, resistance, or drug interactions.
On safety, the companies said no new safety signals were observed; drug-related treatment-emergent adverse events were 35.8% in the olorofim group and 63.9% in the control group. The announcement said the difference was mainly due to a higher proportion of renal events in the AmBisome group. This point is clinically meaningful because, although amphotericin B drugs are important antifungal weapons, their renal burden often limits treatment courses and patient selection.
**Background Context**
Olorofim belongs to the orotomide class of antifungals, with a mechanism of action that differs from currently commonly used antifungal drugs, targeting a key enzyme in the fungal pyrimidine biosynthesis pathway. F2G and Shionogi said that, if approved, it could become the first new-mechanism drug for invasive aspergillosis in more than 20 years; in the United States, olorofim has received orphan drug, qualified infectious disease product, and breakthrough therapy designations. However, these designations are not equivalent to approval, and regulators still need to review the complete data.
Next, F2G plans to submit an application in the United States, while Shionogi is responsible for filings in Europe and Asia. At this stage, several key questions have not yet been fully developed, including longer-term survival and clinical response, performance in different immunocompromised populations, the sequencing or combination-use position with existing antifungals, and the practical role of an oral drug in the care pathway for severe infections. The topline data have given olorofim room to move forward; what will truly determine whether it can reshape the treatment landscape will be the complete Phase 3 data and regulatory reviews in each region.